keytruda isnt the slam dunk everyone thinks

Company: Merck (MSD)

Posted by IOncRep_Merck_7734 · March 16, 2026

Tags: field, strategy, quota

BMS has GPO pull-through in half my accounts.

clinically preferred doesnt matter if youre fighting the formulary payer complexity in onco has gotten worse in 12 months than the prior 3 years combined.

nobody at home office is saying that out loud.

12 upvotes · 5 comments

More from Merck (MSD)